RxDoctor Payments Data

Mary McNeer, MD

Nephrology · Mechanicsville, VANPI 1265438204

Payments from drug & device makers

$1,740in general payments, 2019–2025

Across 51 payments — averaging $34.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$288
  • Otsuka America Pharmaceutical, Inc.$207
  • Biomerieux Inc$177
  • AstraZeneca$177
  • GSK$174
  • Amgen$154
  • plus $563 from 11 others

What the payments were for

  • Consulting fees$17710%
  • Food & beverage$1,26373%
  • Education$19811%
  • Other$1036%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,740 in reported general payments places this provider in the 55th percentile of 298 nephrology providers in Virginia.

See all nephrology providers in Virginia

Medicare billing

Part B allowed, 2024
$445,738
Medicare patients
710
Services billed
6,131

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol98$83,707
VeltassaPatiromer Calcium Sorbitex34$31,917
JardianceEmpagliflozin13$14,845
Cinacalcet Hcl25$10,736
LokelmaSodium Zirconium Cyclosilicate20$8,192
Bumetanide68$2,857
Sevelamer Carbonate28$2,540
Febuxostat13$1,873
Diltiazem 24hr Er (Cd)Diltiazem Hcl15$1,447
Amlodipine Besylate183$1,337
Calcium Acetate26$1,331
Doxazosin Mesylate89$1,286
Losartan Potassium141$1,116
Furosemide178$912
Potassium Citrate ErPotassium Citrate11$869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$177$91,899118 claims
Boehringer IngelheimJardiance$52$14,84513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 298 nephrology providers in Virginia.

Other nephrology in Mechanicsville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →